Company: DNLI
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001714899-25-000193
Chunk: 183

Company: Denali Therapeutics Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 183
---
 Income (Loss)Accumulated DeficitTotal Stockholders' EquitySharesAmountBalance at December 31, 2024144,220,986 $1,768 $2,764,880 $2,020 $(1,538,984)$1,229,684 Issuances under equity incentive plans1,042,249 11 5,224 — — 5,235 Vesting of restricted stock units1,362,487 14 (14)— — — Stock-based compensation— — 76,188 — — 76,188 Net loss— — — — (383,991)(383,991)Other comprehensive loss— — — (919)— (919)Balance at September 30, 2025146,625,722 $1,793 $2,846,278 $1,101 $(1,922,975)$926,197 Balance at June 30, 2025145,685,442 $1,783 $2,820,404 $939 $(1,796,073)$1,027,053 Issuances under equity incentive plans586,914 6 577 — — 583 Vesting of restricted stock units353,366 4 (4)— — — Stock-based compensation— — 25,301 — — 25,301 Net loss— — — — (126,902)(126,902)Other comprehensive income— — — 162 — 162 Balance at September 30, 2025146,625,722 $1,793 $2,846,278 $1,101 $(1,922,975)$926,197 Balance at December 31, 2023138,385,498 $1,711 $2,144,811 $643 $(1,116,211)$1,030,954 Issuance of common stock and pre-funded warrants, net of issuance costs of $4803,244,689 32 499,221 — — 499,253 Issuances under equity incentive plans948,705 10 13,224 — — 13,234 Vesting of restricted stock units1,261,137 11 (11)— —